Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.

British journal of cancer - 1 Aug 2018

Simigdala Nikiana, Pancholi Sunil, Ribas Ricardo, Folkerd Elizabeth, Liccardi Gianmaria, Nikitorowicz-Buniak Joanna, Johnston Stephen R, Dowsett Mitch, Martin Lesley-Ann

Abstract excerpt

BACKGROUND: Resistance to endocrine therapy remains a major clinical problem in the treatment of oestrogen-receptor positive (ER+) breast cancer. Studies show androgen-receptor (AR) remains present in 80-90% of metastatic breast cancers providing support for blockade of AR-signalling. However, clinical studies with abiraterone, which blocks cytochrome P450 17A1 (CYP17A1) showed limited benefit. METHODS: In order...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androstenes
Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to MCF-7 Cells

Share to Neoplasm Recurrence, Local

Share to Neoplasms, Hormone-Dependent

Share to Receptors, Androgen

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 29991699
DOI: 10.1038/s41416-018-0158-y
PMCID: PMC6068155

Genes

ESR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.PMID 29991699Read ↗

The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast CancerSemantic proximity Read ↗

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast CancerSemantic proximity Read ↗

Prostate cancer: An abiraterone ultraresponsive phenotype.Semantic proximity Read ↗

[Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer].Semantic proximity Read ↗

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitorsSemantic proximity Read ↗

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer.Semantic proximity Read ↗

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.Semantic proximity Read ↗

Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer.Semantic proximity Read ↗

Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer.Semantic proximity Read ↗

Exemestane for primary prevention of breast cancer in postmenopausal women.Semantic proximity Read ↗

Physicochemical characteristics of abiraterone acetate used for the treatment of prostate cancerSemantic proximity Read ↗

The menopause, hormone replacement therapy and breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.